Skip to main content
Scott Kopetz, MD, Oncology, Houston, TX

Scott Kopetz MD PhD

Oncology•Houston, TX

Gastrointestinal Medical Oncology at MD Anderson Cancer Center

Join to view full profile

  • 1515 Holcombe BlvdHouston, TX 77030

  • Phone+1 713-792-6161

Dr. Kopetz is on Doximity

As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.
See Dr. Kopetz's full profileAlready have an account?

Summary

  • Scott Kopetz, MD is a Houston, Texas-based oncologist specializing in colorectal cancer, gastrointestinal oncology, colorectal neoplasms, and general medical oncology. He completed his medical degree at Johns Hopkins University School of Medicine in 2001, followed by a residency in Internal Medicine at Duke University Hospital, a fellowship in Hematology and Medical Oncology at the University of Texas Health Science Center at Houston/M D Anderson Cancer Center, and a PhD in Cancer Biology at the University of Texas, Graduate School of Biomedical Sciences. Dr. Kopetz is an acclaimed author with numerous publications in well-regarded scientific journals. He has also served as the Principal Investigator and Contact in several clinical trials concerning advanced solid tumors and colorectal cancer.

Education & Training

  • University of Texas, Graduate School of Biomedical Sciences
    University of Texas, Graduate School of Biomedical SciencesPhD, Cancer Biology, 2005 - 2009
  • University of Texas Health Science Center at Houston/M D Anderson Cancer Center
    University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
  • Duke University Hospital
    Duke University HospitalResidency, Internal Medicine, 2001 - 2004
  • Johns Hopkins University School of Medicine
    Johns Hopkins University School of MedicineClass of 2001

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2022 - 2027
  • MS State Medical License
    MS State Medical License 2022 - 2026
  • OK State Medical License
    OK State Medical License 2020 - 2026
  • TN State Medical License
    TN State Medical License 2022 - 2026
  • TX State Medical License
    TX State Medical License 2004 - 2026
  • AL State Medical License
    AL State Medical License 2022 - 2025
  • Medical Oncology
    American Board of Internal Medicine Medical Oncology
  • Join now to see all

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification ClinicStation, UT MD Anderson Cancer Center, 2013-2015

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Anti-EGFR Resistant Clones Decay Exponentially After Progression: Implications for Anti-EGFR Re-Challenge  
    B Kee, N Garg, M J Overman, V K Morris, B Johnson, J Wu, J H Strickler, S Kopetz, X Liu, D S Hong, Annals of Oncology
  • Colorectal Premalignancy Is Associated with Consensus Molecular Subtypes 1 and 2  
    L M Ellis, P M Lynch, J A Willis, S Kopetz, Annals of Oncology
  • DNA Sequencing of Small Bowel Adenocarcinomas Identifies Targetable Recurrent Mutations in the ERBB2 Signaling Pathway  
    Scott Kopetz, Michael T Tetzlaff, Michael J Overman, Huamin Wang, Clinical Cancer Research

Press Mentions

  • Proteins to Precision Robotics: Texas Researchers Collaborate to Break Ground in Cancer Care
    Proteins to Precision Robotics: Texas Researchers Collaborate to Break Ground in Cancer CareJune 15th, 2026
  • Two Phase 3 Trials at ASCO GI Support New Frontline Colorectal Cancer Options
    Two Phase 3 Trials at ASCO GI Support New Frontline Colorectal Cancer OptionsJanuary 9th, 2026
  • BRAF V600E–Mutant Colorectal Cancer: First-Line Encorafenib, Cetuximab, and FOLFIRI
    BRAF V600E–Mutant Colorectal Cancer: First-Line Encorafenib, Cetuximab, and FOLFIRIJanuary 6th, 2026

Grant Support

  • Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancerMASSACHUSETTS GENERAL HOSPITAL2022–2027
  • Paul Calabresi Clinical Oncology AwardUNIVERSITY OF TX MD ANDERSON CAN CTR2000–2027
  • Paul Calabresi Clinical Oncology AwardUNIVERSITY OF TX MD ANDERSON CAN CTR2000–2027
  • MDACC-PREDICTUNIVERSITY OF TX MD ANDERSON CAN CTR2020–2025
  • MD Anderson Cancer Center SPORE in Gastrointestinal CancerUNIVERSITY OF TX MD ANDERSON CAN CTR2019–2025

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence:

Dr. Scott Kopetz, Dr. Scott Kopetz, MD, Dr. S Kopetz